QUALITY BY DESIGN BASED BIOANALYTICAL METHOD DEVELOPMENT FOR ESTIMATION OF ANTIDIABETIC DRUGS IN HUMAN PLASMA BY RP-HPLC METHOD
International Journal of Drug Delivery Technology · 10.06.2026 · 16 (47s)
DOI: 10.25258/ijddt.16.47s.147 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 10.06.2026. Verfasst von Shruti G. Kole und 11 weiteren Autor:innen.
Abstract (Originalsprache)
This study was designed to create and check a quick, specific, and quality by design (QbD) based reversed-phase high-performance liquid chromatography (RP-HPLC) method for measuring two drugs, Dapagliflozin and Teneligliptin, at the same time in human blood. The analysis was done using an Agilent Technologies 1100 RPHPLC system with a C18 column that is 250 mm long, 4.6 mm wide, and 5 micrometers thick. To fine-tune the method, a Central Composite Design (CCD) approach was used. The mobile phase was made of methanol and a solution of water with 0.1% acetic acid. It flowed at 0.7 mL per minute and the detector was set to 240 nm. The time it took for each drug to pass through the column was 4.588 minutes for Teneligliptin and 8.130 minutes for Dapagliflozin. Blood samples were processed with a straightforward and fast method to remove proteins. The method was tested according to ICH M10 guidelines and showed strong linearity across a concentration range of 5 to 25 micrograms per milliliter, with a very high correlation coefficient (r² = 0.999). The minimum amount of drug that could be detected (LOD) and the lowest amount that could be measured accurately (LOQ) for Dapagliflozin were 0.060 and 0.183 micrograms per millilitre, respectively. For Teneligliptin, these values were 0.076 and 0.232 micrograms per milliliter. The accuracy, consistency, and recovery of the method were all within acceptable limits. In summary, the new method is easy to use, fast, accurate, and reliable, making it a good choice for everyday use in bioanalytical and pharmaceutical testing.
Zitieren
APA
Kole, S. G., Tambavekar, D. D., Ghotane, R. B., Nagargoje, G., Kore, B., Kote, S., Dalvi, P., Ghatage, S., Sakhare, R., Powar, D., Patil, P. B., & Mali, S. S. (2026). QUALITY BY DESIGN BASED BIOANALYTICAL METHOD DEVELOPMENT FOR ESTIMATION OF ANTIDIABETIC DRUGS IN HUMAN PLASMA BY RP-HPLC METHOD. International Journal of Drug Delivery Technology, 16(47s). https://doi.org/10.25258/ijddt.16.47s.147
Vancouver
Kole SG, Tambavekar DD, Ghotane RB, Nagargoje G, Kore B, Kote S, et al. QUALITY BY DESIGN BASED BIOANALYTICAL METHOD DEVELOPMENT FOR ESTIMATION OF ANTIDIABETIC DRUGS IN HUMAN PLASMA BY RP-HPLC METHOD. International Journal of Drug Delivery Technology. 2026;16(47s). doi:10.25258/ijddt.16.47s.147
BibTeX
@article{Kole2026,
author = {Kole, Shruti G. and Tambavekar, Dipti D. and Ghotane, Rajanikant B. and Nagargoje, Ganesh and Kore, Bhakti and Kote, Shraddha and Dalvi, Purva and Ghatage, Sakshi and Sakhare, Revati and Powar, Dhanashree and Patil, Pramod B. and Mali, Sachin S.},
title = {QUALITY BY DESIGN BASED BIOANALYTICAL METHOD DEVELOPMENT FOR ESTIMATION OF ANTIDIABETIC DRUGS IN HUMAN PLASMA BY RP-HPLC METHOD},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {47s},
doi = {10.25258/ijddt.16.47s.147}
}
EUVIMED